SCHEMBL24251096

SCHEMBL24251096

Cc1ccc(C(=O)Nc2ccc(N3CCN(C)CC3)cc2C(F)(F)F)cc1Nc1nccc(-c2cnccn2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 11/20 0.57
BCR P11274 6/20 0.57
KDR P35968 6/20 0.57
NR1I2 O75469 1/20 0.57
ADORA3 P0DMS8 1/20 0.57
PTGS1 P23219 1/20 0.57
CHRNA4 P43681 1/20 0.57
PDE3A Q14432 1/20 0.57
KIT P10721 8/20 0.57
LDLR P01130 3/20 0.57
PCSK9 Q8NBP7 3/20 0.57
LYN P07948 3/20 0.57
PDGFRA P16234 4/20 0.54
LCK P06239 1/20 0.51
JAK3 P52333 1/20 0.51
TEK Q02763 1/20 0.51
MAPK14 Q16539 1/20 0.51
PDGFRB P09619 2/20 0.50
EGFR P00533 1/20 0.49
BRAF P15056 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29551785 1.00 ABL1 (0.57) ABL1BCRKDRNR1I2ADORA3
SCHEMBL24251154 0.91 ABL1 (0.69) ABL1BCRKDRADORA3KIT
SCHEMBL29551226 0.91 ABL1 (0.69) ABL1BCRKDRADORA3KIT
SCHEMBL29551613 0.87 ABL1 (0.54) ABL1BCRKDRNR1I2ADORA3
SCHEMBL24251060 0.87 ABL1 (0.54) ABL1BCRKDRNR1I2ADORA3
SCHEMBL24250905 0.87 KIT (0.61) ABL1BCRKDRKITLDLR
SCHEMBL29551572 0.87 KIT (0.61) ABL1BCRKDRKITLDLR
SCHEMBL29551545 0.84 KIT (0.63) ABL1BCRKDRKITLDLR
SCHEMBL24251163 0.84 KIT (0.63) ABL1BCRKDRKITLDLR
SCHEMBL24250994 0.83 ABL1 (0.65) ABL1BCRKDRADORA3KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114127065-A Compounds for the treatment of neurodegenerative diseases and cancer 鸿仪有限责任公司 2022-03-01 CN claimed
US-20220048893-A1 Compounds for Treating Neurodegenerative Diseases and Cancers HONGYI & ASS LLC (US) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048893-A1 Compounds for Treating Neurodegenerative Diseases and Cancers SNCA, NGF, SLC18A2 ABL1 695/4885BCR 1219/4885KDR 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.